Based on results from REWIND, dulaglutide is the first GLP-1 receptor agonist to be approved for both primary and secondary CV prevention in type 2 diabetes.
Which 5 diets are best for your diabetes patients out of the 35 ranked most popular by US News & World Report health experts?
Over 70% of US adults with diabetes have hypertension, 15.6% of these patients have an A1c value >9%, and more fast facts on diabetes risk factors and patient characteristics.
The new 3-in-1 oral therapy may help reduce treatment burden for T2D patients who most often require multiple agents.
A US diabetes diagnosis is made every 21 seconds; 40% of millennials with T2DM can't pay for treatment. And there is more PCPs will want to know.
The year 2020 comes primed with 2019's approvals and expanded indications for drugs to treat patients with diabetes.
Treatment with liraglutide for 26 weeks had no impact on bone resorption in patients with T2D, say authors of a new study.
Dapagliflozin received FDA priority review for reducing risk of CV death in adults with heart failure with reduced ejection fraction.
Type 1 diabetes patients who used the new system increased by 2.6 hours/day the amount of time spent in target blood glucose level range.
Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.